New Vaginal Swab Test Aims to Spare Women Painful Endometrial Biopsies
A simple vaginal swab test is currently under clinical evaluation with the goal of helping women experiencing abnormal bleeding determine if they have endometrial cancer without immediately undergoing an invasive biopsy. Developed by the California-based company PinkDx, the diagnostic tool is designed specifically for individuals already reporting symptoms such as postmenopausal bleeding.
Understanding Traditional Diagnostic Methods
Endometrial cancer develops in the lining of the uterus. Standard medical evaluations often involve a transvaginal ultrasound, which uses an internal probe to measure the thickness of the uterine lining, or an endometrial biopsy. During a biopsy, a clinician passes a thin tube into the uterus to scrape away a small tissue sample for laboratory analysis. Both procedures can cause significant physical discomfort for patients.
Furthermore, medical professionals note that traditional biopsies fail to collect an adequate amount of tissue approximately 30% of the time in postmenopausal women. This limitation can occur if the uterine lining is excessively thin or if the cervical canal is too narrow to permit the necessary instruments.
How the Swab Test Works
As cancer cells within the uterus degenerate, they shed microscopic fragments of genetic material that carry distinct tumor fingerprints. These cellular fragments can drift downward into the vaginal canal, where a clinician can collect them using a standard swab for specialized laboratory testing.
In an initial preliminary evaluation involving 27 women who were scheduled for a hysterectomy, PinkDx researchers successfully detected these genetic signals even from swabs collected at the vaginal opening. However, experts emphasize that this initial test group was very small and its findings require rigorous confirmation.
Current Clinical Trial and Future Steps
A larger clinical trial is currently underway across 16 United States sites, with plans to enroll approximately 3,000 women. Company representatives indicate that early results remain on target. Researchers have established specific performance benchmarks for the diagnostic tool: the swab aims to correctly identify at least 90% of cancers while accurately ruling out the disease in at least half of the women who do not have it, thereby reducing false alarms.
Independent experts, including Dr. Nicolas Wentzensen, deputy director of the Clinical Genetics Branch at the National Cancer Institute, noted that if these projected numbers are validated in the broader study, the swab could potentially serve as an initial screening step that spares a significant portion of the population from immediate biopsies. Nevertheless, individuals who receive a positive test result would likely still require a confirmatory biopsy, while those who test negative must continue following up with their healthcare providers to investigate alternative causes for their symptoms.
Regulatory Path and Availability
Because PinkDx plans to process the diagnostic test exclusively within its own laboratory facility, the procedure does not require formal approval from the U.S. Food and Drug Administration. The company anticipates completing certification through the Centers for Medicare and Medicaid Services, with potential availability for patients targeted by mid-2027.
